Proton Pump Inhibitors: Have We Gone Too Far?

How to manage risk and help your patients

Kerry Dunbar, MD, PhD, AGAF, FASGE
Professor of Medicine
Associate Program Director Internal Medicine
VA Gastroenterology Section Chief

Outline

- FDA Indications for PPIs
- Other accepted uses of PPIs
- Adverse events reported with PPIs
- Balancing the risk and benefits

Proton Pump Inhibitors

- First introduced in the US in 1989
- Block the H+K+ ATPase in parietal cells

- Pre-PPI era
  - Histamine-2 receptor antagonists (H2RAs) available for acid suppression
  - Cimetidine introduced in 1976



Castell, AJG 2002. Everhart, Gastro 2009. Kantor, JAMA 2015

FDA-Approved Indications for PPIs

- Peptic ulcer disease
  - Treatment
  - Prevention of PUD with NSAID use
  - As part of treatment of H. pylori infection
  - Maintenance treatment of duodenal ulcer
- Gastroesophageal Reflux Disease
  - Treatment
  - Healing of erosive esophagitis
  - Maintenance of healed erosive esophagitis
- Treatment of gastric acid hypersecretion – Zollinger-Ellison syndrome

Peptic Ulcer Disease and PPIs

- Population study from Sweden, 1974-2002
- After PPI introduction
  - Decreased incidence of PUD bleeding and perforation
- Decreased complications despite increasing NSAID and ASA use

- Consider a PPI in patients on NSAIDS at high risk for PUD complications
  - Prior PUD
  - Age > 65
  - Use of concurrent aspirin, steroids, anticoagulants

Bleeding



Hermannson, BMC Gastro 2009. Lanza, AGJ 2009.

PPIs are Effective Treatment for GERD



- Compared to H2RAs and antacids, PPIs are more effective for
  - Healing erosive esophagitis
  - Controlling GERD symptoms
- FDA approved dose for GERD is once-daily dosing
- Often used twice daily in clinical practice
- Dose before meals
- Use lowest effective dose to control symptoms



Don't forget about diet and lifestyle changes

Wang, WJG 2005

Zollinger-Ellison Syndrome

- Gastrinoma – neuroendocrine tumor found in the pancreas or duodenum



- 4 to 10-fold increase in gastric acid production
- High dose PPIs are part of the treatment

Other Accepted Uses of PPIs

- Chemoprevention of esophageal cancer in patients with Barrett's esophagus
- Treatment of eosinophilic esophagitis
- Treatment of non-ulcer dyspepsia
- Stress ulcer prophylaxis in ICU patients

PPIs and Barrett's Esophagus

- 5% of the US population has Barrett's esophagus (BE)
  - 10-15% of patients with chronic GERD have BE

- PPIs reduce the risk of progression to cancer
  - 71% reduction of esophageal adenocarcinoma and high grade dysplasia
  - Dose-response present: benefit seen with > 2 years of use



Spechler, Am J Gastro 2006. Singh, Gut 2014

Eosinophilic Esophagitis

- Eosinophilic infiltration of the esophageal mucosa → esophageal dysfunction

- PPIs are a recommended treatment for eosinophilic esophagitis
- PPI treatment leads to
  - Histologic response in 51%
  - Symptom improvement in 61% of pts





Dellon, AJG 2013. Straumann, Gut 2014. Lucendo, UEG journal 2017. Lucendo, CGH 2016.

Dyspepsia and PPIs

- Epigastric discomfort
- Post-prandial fullness
- Early satiety
- Epigastric burning
- Not classic heartburn
- Endoscopy is normal



Moayyeddi, American College of Gastroenterology Dyspepsia Guideline, Am J Gastro 2017

Stress Ulcer Prophylaxis for Patients in the ICU

- Ulceration secondary to impaired mucosal protection, poor perfusion



- SUP-ICU trial randomized 3298 ICU pts to 40 mg IV pantoprazole or placebo
- Clinically important GI bleeding seen in
  - 4.2% pts on placebo
  - 2.5% pts on PPI
- No significant difference in mortality or major complications

Krag, NEJM 2018

PPIs Fix Everything…….



PPIs and Risk

What to say when your patients, parents, and neighbors ask you questions

Reported Adverse Effects of PPI Treatment



Vaezi, Gastro 2017

UT Southwestern Medical Center

Should we Stop Using PPIs?



RCT of PPI Safety in Patients Taking Rivaroxaban or Aspirin

- 17,598 patients > age 65 with cardiovascular or peripheral arterial dise
- Comparing patients who got PPI vs. placebo:

- **NO** difference in pneumonia, fractures, chronic kidney disease, dementia, cancer
  - More enteric infections with PPI use - 1.4% vs. 1%
  - Clostridium difficile infectio s. 4)

Moayyedi P, Gastro 2019

Long-Term PPI Risks – Questions to Ask

- Most of the PPI studies are observational studies
- Observational studies examine the association between PPIs and Disease X

1. Is there a **biological explanation**?
2. How **strong** is the association between PPIs and disease X?
3. Is there a **dose/duration** effect?
4. Is the association between PPIs and X **consistent**?
5. Seen in **more than one** research study?
6. Beware the 'zone of potential bias' = odds ratios of 0.3 – 4.0, relative risks of 2-3.

Vaezi, Gastro 2017. Grimes, Obs Gyn 2012. Hill AB, Proc R Soc Med 1965.

Clopidogrel, Myocardial Infarction, and PPIs

- **Biological explanation**: PPIs and clopidogrel are both metabolized by CYP2C19.
  - PPI may decrease the active metabolite of clopidogrel → less inhibition of platelet aggregation → myocardial infarction
- 2009 FDA black box warning for PPI + clopidogrel
- Systematic review of PPI use with clopidogrel
  - 30 observational studies (**weaker** evidence): More ischemic cardiac events with combined use
  - 4 randomized controlled trials (**stronger** evidence) – no difference in rate of ischemic events, less GI bleeding
  - **Weak** association - HR 1.16
- Meta-analysis of newer studies showed similar findings – **no** cardiac risk seen in RCTs of PPI use

PPIs and Diarrhea

- **Biological explanation**: With PPI use, fewer bacteria killed by stomach acid → infectious diarrhea
- Risk of bacterial gastroenteritis (salmonella, campylobacter) with PPI use
  - OR 1.33 (**weak** association)
  - Association is **consistent** across studies
- Risk of C. difficile with PPI use
  - Increased risk of C. diff (OR 1.99), **weak** association
  - For antibiotic + PPI (OR 1.96)
  - Increased risk of C. diff recurrence (OR 2.5)
  - **Moderate** evidence, **consistent** across meta-analyses

Eom, CMAJ 2011. Trifan World J Gastro 2017. Filion, Gut 2013. Kwok, Am J Gastro 2012

PPIs and Kidney Disease



- **Biological explanation**: PPIs can cause repeated episodes of acute interstitial nephritis (AIN) → chronic kidney disease
- Nested-case control study of 572,661 patients
  - OR for AIN with PPI use 5.16 (**moderate** association)
  - Incidence rate of AIN for
    - Current use of PPIs – 11.98 cases /100,000 pts
    - Past use of PPIs – 1.68 cases/100,000 pts
- Evidence for association between AIN and PPIs is **moderate** and **consistent**

Blank, Kidney Intl 2014. Atoniou, CMAJ Open 2015. Lazarus ,JAMA Int Med 2016

PPIs and Bone Fractures

- **Biological explanation**: PPIs can reduce absorption of calcium carbonate → osteoporosis → fractures
- Some studies show a **dose/duration** effect
  - Risk higher with longer use, higher doses
- Meta-analysis - 10 studies, 233,210 fracture pts
  - Moderate increase in risk of hip /spine fractures with PPI use, risk ratio (RR) 1.25, **weak** association
  - 6 studies show increased risk with PPI use, 2 studies show no difference, 2 show PPIs protect against fracture**: not consistent**



Ngamruengphong Am J Gastro 2011. Zhou, Osteoporos Int 2016

PPIs and Pneumonia

- **Biological explanation:** Gastric acid kills bacteria → PPIs allow bacteria to grow in the stomach
- Risk of community-acquired pneumonia with PPI use
  - Meta-analysis of 8 observational studies
  - Risk of CAP in pts on PPI, OR 1.27 (**weak** association)
  - Risk of CAP with H2RA, OR 1.22
- 2nd meta-analysis of 5 recent studies of CAP
  - Association between PPI and pneumonia seen in 1 study, but not seen in 4 other studies.
    - **Not consistent**



Eom, CMAJ 2011. Lambert, PLoS One 2015. Filion, Gut 2013. 2016

What Now?



New PPI studies are published every month

What if some of the risks are real?

How do we manage risk?

Issues to Consider – Observational Studies





Bloomberg.com

Assessing Risk – Absolute Excess Risk

- Lots of different terms used to describe risk
  - Odds ratio, relative risk, hazard ratio
- Depending how it's reported, numbers can look VERY scary
- Example : Chronic kidney disease (CKD) is more common in PPI users, hazard ratio of 1.5

Scary newspaper headline:

50% increase in kidney disease in PPI users!!!

- 10-year absolute excess risk for CKD between PPI+ and no PPI = 3.3%
- So with 10 years of PPI use, the risk difference for getting CKD was only 3.3%

Lazarus, JAMA Int Med 2016. Vaezi, Gastro 2017

Assessing Risk - Number Needed to Harm

- COMPASS trial – randomized to PPI or placebo and aspirin, rivaroxaban, or combo
  - More enteric infections with PPI use - 1.4% vs. 1%
  - C. difficile infections rare, but more common in PPI group (9 cases vs. 4)
- Number Needed to Harm (NNH)
  - Number of patients who take the treatment for 1 patient to have the adverse event
- NNH C. difficile – 5266
- NNH other enteric infections - 900

Moyyaeddi, Gastro 2019

Choosing Wisely – GERD



For pharmacological treatment of patients with GERD, long-term acid suppression therapy (PPIs or H2RAs) should be titrated to the lowest effective dose needed to achieve therapeutic goals

https://www.choosingwisely.org/societies/american-gastroenterological-association/

Bye-Bye PPI: Choosing Wisely in Canada



Managing Risk – Who Needs a PPI?

- Patients with the FDA-approved indications
  - GERD
  - Peptic ulcer disease
  - Zollinger-Ellison
- Other accepted indications
  - Patients with Barrett's esophagus for cancer prevention
  - Some patients with eosinophilic esophagitis
  - Some patients with non-ulcer dyspepsia
  - Some patients in the ICU for stress ulcer prophylaxis (short-term)

Use with caution for unexplained GI symptoms

Managing Risk for Patients Taking PPIs

- For patients with GERD – encourage healthy diet and lifestyle changes
- Revisit PPI dosing periodically
  - Have symptoms improved?
  - Are PPIs taken properly ?
- Address patient concerns about long – term PPI use
- Statistical correlation does not equal causation
- Try to give patients a sense of the absolute excess risk
  - Not everyone who takes a PPI breaks a bone, gets kidney disease,

Be smart about PPI use → lowest effective dose

Guidance from the American College of Gastroenterology

- PPIs are the most effective medical treatment for GERD
- Some medical studies have identified an association between the long-term use of PPIs and the development of numerous adverse conditions including intestinal infections, pneumonia, stomach cancer, osteoporosis-related bone fractures, chronic kidney disease, deficiencies of certain vitamins and minerals, heart attacks strokes, dementia, and early death.
- Those studies have flaws, are not considered definitive, and do not establish a cause-and-effect relationship between PPIs and the adverse conditions
- High quality studies have found that PPIs do not significantly increase the risk of any of these conditions except intestinal infections
- Nevertheless, we cannot exclude the possibility that PPIs might confer a small increase in the risk of developing these adverse conditions.
- For the treatment of GERD, gastroenterologists generally agree that the well-established benefits of PPIs far outweigh their theoretical risks.

Katz, Dunbar, Schnoll-Sussman, Spechler. ACG GERD Guideline, AJG 2022

Questions?

American Gastroenterological Association Clinical Practice Update on De-Prescribing PPIs

1. does the patient still have an indication for PPI?
2. if no, consider deprescribing
3. If on BID PPI, consider a trial of daily.
4. complicated GERD (stricture, severe esophagitis, ulcer) – don't d/c the PPI
5. BE, EoE, idiopathic pulmonary fibrosis – don't d/c the PPI
6. assess GI bleeding risk before de-prescribing
7. don't stop if high risk
8. may get symptom rebound, it get better
9. can taper or just stop
10. deprescribe based on lack of indication, not because of concern for AEs.

Targownik, et al. Gastro 2022

Treatment of GERD – Role of PPIs